RNAZ
Transcode Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$5.41M
P/E Ratio
—
EPS
$-3.71
Beta
1.40
52W High
$20.99
52W Low
$3.82
50-Day MA
$7.23
200-Day MA
$9.27
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Transcode Therapeutics Inc
TransCode Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development and commercialization of drugs for the treatment of metastatic diseases. The company is headquartered in Boston, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-19.12M |
| Operating Margin | 0.00% |
| Return on Equity | -46.30% |
| Return on Assets | -14.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $11.27 |
| Price-to-Book | 4.15 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.59 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 950,300 |
| Float | 835,400 |
| % Insiders | 9.22% |
| % Institutions | 8.62% |
Historical Volatility
HV 10-Day
123.66%
HV 20-Day
106.00%
HV 30-Day
89.74%
HV 60-Day
69.78%
HV Rank
54.8%
Volatility is currently expanding
More HEALTHCARE Stocks
Data last updated: 6/13/2026